Remove tag msd
article thumbnail

Cancer research drugs: Where is the innovation?

Drug Discovery World

Click’ chemistry used to tag proteins made by cancer cells. Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. A team from the University of Geneva (UNIGE) has found a way to overcome chemotherapy resistance in colorectal cancer.

Drugs 52
article thumbnail

Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to.

The Pharma Data

Merck known as MSD outside the United States and Canada, moment blazoned that it has withdrawn its Premerger Announcement and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “ HSR Act”), in connection with Merck’s pending accession of Acceleron PharmaInc. Nasdaq XLRN). About Merck.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Oslo Medicines Initiative asks how to balance innovation incentivisation with security of access

pharmaphorum

This evolution is leading to additional health benefits and health gains, but they are accompanied by major concerns, as very high price tags raise questions about their affordability.”. In recent years, revolutionary medicines have come with price tags to match, but this is simply a symptom of our current model.

article thumbnail

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

Nageatte Ibrahim, MD, Vice President, Oncology & Global Clinical Development, MSD, on: ‘The new age of immunotherapy: From checkpoint inhibitors to vaccines’. Fabian Mohr, PhD, Vice President Research & Development, IBA Lifesciences, on: ‘Developing a robust affinity tag platform using engineered streptavidin’.

Protein 59
article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

After the plenary keynote session, there will be a keynote presentation by Mark McCoy, PhD, Principal Scientist, Quantitative Biosciences, MSD, on higher-order structure, behaviour, and interactions of novel biotherapeutics. Thereafter, there will be two presentations followed by two luncheon presentations.